Icosavax Highlights Six Months Durability Data For Respiratory Syncytial Virus Vaccine Candidate – Icosavax (NASDAQ:ICVX)
Icosavax Inc ICVX provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These new data demonstrate a sustained neutralizing antibody (nAb) response against…